Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study)

BACKGROUND: The incidence of nonalcoholic fatty liver disease (NAFLD) has increased recently and is related to obesity and the associated surge in type 2 diabetes mellitus (DM) and metabolic syndrome diagnoses. We aim to compare the effectiveness of tofogliflozin and pioglitazone treatment on hepati...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozaki, Anna, Yoneda, Masato, Kessoku, Takaomi, Iwaki, Michihiro, Kobayashi, Takashi, Honda, Yasushi, Ogawa, Yuji, Imajo, Kento, Sakai, Eiji, Taguri, Masataka, Yamanaka, Takeharu, Iwasaki, Tomoyuki, Kurihashi, Takeo, Saito, Satoru, Nakajima, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956674/
https://www.ncbi.nlm.nih.gov/pubmed/31956725
http://dx.doi.org/10.1016/j.conctc.2019.100516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956674/
https://www.ncbi.nlm.nih.gov/pubmed/31956725
http://dx.doi.org/10.1016/j.conctc.2019.100516

Ejemplares similares